Ann: Updated Presentation to Support CEO Partnering Meetings, page-25

In relation to this presentation I found the daptomycin injectable comments quite interesting.The product is assessed as further developed than the propofol Terumo product and is subject to a current in house development progam.The product is available for partnering recognizing 5% reciprocal royalty with Mylan and Mylans past interest in this product.
To the best of my knowledge there are about 8 other major pharma companies in the generic daptomycin injectable space [including Mylan] Another pharma partnering with the POH product might just see an opportunity to impact on this daptomycin generic market considerably.
All just food for thought.
Kens